Almac Group, the global contract development and manufacturing organisation, has confirmed a £16 million investment to expand its formulation and analytical development services to meet ongoing client demand.
The company announced the successful conclusion to negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England – a world-class science, technology and enterprise park. Specifically, Almac will occupy the formulation development and analytical testing facilities at the site which will complement existing development & GMP services offered from its Craigavon NI Headquarters.
The Charnwood facilities were originally designed and built by a global Pharma company as part of its in-house formulation development, clinical manufacturing & analytical testing capabilities. Almac has now commenced recommissioning of the facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing, creating approximately 180 new jobs in the next 5 years. With an initial investment into the Charnwood site of ~£16m in process and analytical technologies, an operational start date is targeted for Q1 2017.
Graeme McBurney, Managing Director, Almac Pharma Services commented: “As we experience increased client demand for our pharmaceutical development and niche commercial manufacturing services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and capability and further demonstrating our continued commitment to support our global clients in the development and manufacturing of their drug products.”